MarketCap
Facebook
X
Telegram
Clovis Oncology Balance Sheet 2021-2009 | CLVS
Brief overview of Clovis Oncology's assets and capital
The comparison uses five available annual reports from the 2017–2021 interval.
Assets fell from $735.2 million to $472.8 million. This may reflect either deliberate optimization or a reduction in business scale.
Funding shifted toward liabilities: they gained +104.5%, compared with -35.7% for assets.
Net asset value fell below zero as liabilities exceeded assets. This is one of the most material balance sheet risks.
The cash reserve occupies 30.3% of the balance sheet, previously 63.1%. It is one marker of short-term resilience.
Retained earnings are negative at -$2.9 billion. This reduces the formal capital cushion, although large shareholder returns may have contributed.
Overall picture
Clovis Oncology's balance sheet looks stretched: reliance on liabilities and a limited capital cushion increase sensitivity to weaker results.
Annual Balance Sheet Clovis Oncology
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
293 M | 195 M | 483 M | 366 M | -182 M | 64.9 M | 1.13 M | -195 M | -323 M | -144 M | -138 M | - | - |
Long Term Debt |
437 M | 435 M | 645 M | 588 M | 282 M | 281 M | 280 M | 288 M | - | - | - | - | - |
Total Non Current Liabilities |
- | 579 M | 711 M | 591 M | 286 M | 303 M | 337 M | 407 M | 131 M | 338 K | 656 K | - | - |
Total Current Liabilities |
125 M | 185 M | 133 M | 126 M | 81.5 M | 65.6 M | 75.6 M | 47.8 M | 21 M | 12.2 M | 11 M | - | - |
Total Liabilities |
752 M | 764 M | 844 M | 717 M | 368 M | 368 M | 413 M | 446 M | 152 M | 12.5 M | 11.7 M | - | - |
Retained Earnings |
-2.88 B | -2.61 B | -2.24 B | -1.84 B | -1.48 B | -1.13 B | -782 M | -429 M | -269 M | -184 M | -110 M | - | - |
Total Assets |
473 M | 606 M | 670 M | 864 M | 735 M | 365 M | 713 M | 777 M | 650 M | 146 M | 143 M | - | - |
Cash and Cash Equivalents |
143 M | 240 M | 162 M | 222 M | 464 M | 216 M | 279 M | 483 M | 323 M | 144 M | 138 M | 10.5 M | 57.3 M |
Book Value |
-279 M | -159 M | -174 M | 146 M | 368 M | -3.63 M | 301 M | 332 M | 498 M | 133 M | 132 M | - | - |
Total Shareholders Equity |
-279 M | -159 M | -174 M | 146 M | 368 M | -3.64 M | 301 M | 332 M | 498 M | 133 M | 132 M | -54.8 M | -17.1 M |
All numbers in USD currency
Quarterly Balance Sheet Clovis Oncology
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | 443 M | 438 M | 437 M | 437 M | 436 M | 436 M | 435 M | 435 M | 505 M | 505 M | 525 M | 645 M | 644 M | 577 M | 576 M | 588 M | 575 M | 574 M | 283 M | 282 M | 282 M | 282 M | 281 M | 281 M | 281 M | 281 M | 281 M | 280 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 150 K | 211 K | 270 K | 338 K | 408 K | 484 K | 555 K | 656 K | 656 K | 656 K | 656 K |
Total Liabilities |
- | 765 M | 761 M | 755 M | 752 M | 733 M | 779 M | 770 M | 764 M | 756 M | 726 M | 729 M | 844 M | 804 M | 716 M | 710 M | 717 M | 658 M | 655 M | 373 M | 368 M | 506 M | 506 M | 362 M | 368 M | 342 M | 355 M | 412 M | 413 M | 477 M | 463 M | 452 M | 446 M | 443 M | 157 M | 157 M | 152 M | 152 M | 152 M | 152 M | 12.5 M | - | - | - | - | - | - | - |
Retained Earnings |
- | -3.06 B | -3.01 B | -2.94 B | -2.88 B | -2.81 B | -2.75 B | -2.68 B | -2.61 B | -2.51 B | -2.44 B | -2.34 B | -2.24 B | -2.14 B | -2.05 B | -1.93 B | -1.84 B | -1.74 B | -1.65 B | -1.55 B | -1.48 B | -1.43 B | -1.36 B | -1.19 B | -1.13 B | -1.06 B | -995 M | -865 M | -782 M | -662 M | -564 M | -492 M | -429 M | -374 M | -334 M | -300 M | -269 M | -269 M | -269 M | -269 M | - | - | - | - | - | - | - | - |
Total Assets |
- | 347 M | 393 M | 452 M | 473 M | 508 M | 572 M | 549 M | 606 M | 593 M | 628 M | 602 M | 670 M | 717 M | 686 M | 785 M | 864 M | 891 M | 968 M | 679 M | 735 M | 805 M | 850 M | 537 M | 365 M | 399 M | 468 M | 645 M | 713 M | 892 M | 663 M | 705 M | 777 M | 832 M | 599 M | 629 M | 650 M | 360 M | 375 M | 131 M | 146 M | 165 M | 180 M | 124 M | 143 M | 143 M | 143 M | 143 M |
Cash and Cash Equivalents |
- | 58.3 M | 94.6 M | 122 M | 143 M | 172 M | 230 M | 191 M | 240 M | 225 M | 261 M | 163 M | 162 M | 201 M | 109 M | 123 M | 222 M | 291 M | 468 M | 374 M | 464 M | 611 M | 492 M | 276 M | 216 M | 244 M | 228 M | 220 M | 279 M | 355 M | 236 M | 292 M | 483 M | 517 M | 273 M | 304 M | 323 M | 357 M | 372 M | 130 M | 144 M | 162 M | 177 M | 121 M | 138 M | 138 M | 138 M | 138 M |
Book Value |
- | -418 M | -368 M | -303 M | -279 M | -225 M | -207 M | -221 M | -159 M | -163 M | -97.4 M | -127 M | -174 M | -87.5 M | -30 M | 74.9 M | 146 M | 234 M | 312 M | 306 M | 368 M | 299 M | 344 M | 174 M | -3.63 M | 57 M | 113 M | 233 M | 301 M | 414 M | 200 M | 253 M | 332 M | 388 M | 442 M | 473 M | 498 M | 209 M | 223 M | -20.3 M | 133 M | 165 M | 180 M | 124 M | 143 M | 143 M | 143 M | 143 M |
Total Shareholders Equity |
- | -418 M | -368 M | -303 M | -279 M | -225 M | -207 M | -221 M | -159 M | -163 M | -97.4 M | -127 M | -174 M | -87.5 M | -30 M | 74.9 M | 146 M | 234 M | 312 M | 306 M | 368 M | 299 M | 344 M | 174 M | -3.64 M | 57 M | 113 M | 233 M | 301 M | 414 M | 200 M | 253 M | 332 M | 388 M | 442 M | 473 M | 498 M | 346 M | 363 M | 120 M | 133 M | 153 M | 170 M | 114 M | 132 M | 132 M | 132 M | 132 M |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Clovis Oncology, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Canada
China
USA
France
Singapore
Britain
Germany
Israel
Russia
Belgium
Niderland
Irlanda
